Edwards Lifesciences (NYSE:EW) Earns Outperform Rating from Royal Bank Of Canada

Edwards Lifesciences (NYSE:EW)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank Of Canada in a research note issued on Tuesday,Benzinga reports. They currently have a $100.00 price objective on the medical research company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 12.18% from the stock’s current price.

Several other analysts also recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. TD Cowen reissued a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Robert W. Baird increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Stock Up 3.3%

NYSE EW traded up $2.86 during trading hours on Tuesday, reaching $89.14. 1,096,056 shares of the company’s stock traded hands, compared to its average volume of 4,813,453. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $89.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a 50-day simple moving average of $82.88 and a 200 day simple moving average of $83.10. The firm has a market cap of $51.33 billion, a PE ratio of 47.44, a PEG ratio of 2.13 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,038 shares of company stock valued at $6,683,255. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Norges Bank purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $238,688,000. Marshall Wace LLP increased its stake in shares of Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Edwards Lifesciences by 132.4% in the 1st quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after purchasing an additional 2,212,208 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.